摘要
Mineral and bone disorder(MBD)in chronic kidney disease(CKD)is tightly linked to cardiovascular disease(CVD).In this study,we aimed to compare the prognostic value of nine MBD biomarkers to determine those associated best with adverse cardiovascular(CV)outcomes and mortality.In 5217 participants of the German CKD(GCKD)study enrolled with an estimated glomerular filtration rate(eG FR)between 30–60 mL·min-1 per 1.73 m2 or overt proteinuria,serum osteoprotegerin(OPG),C-terminal fibroblast growth factor-23(FGF23),intact parathyroid hormone(iP TH),bone alkaline phosphatase(BAP),cross-linked C-telopeptide of type 1 collagen(CTX1),procollagen 1intact N-terminal propeptide(P1NP),phosphate,calcium,and 25-OH vitamin D were measured at baseline.Participants with missing values among these parameters(n=971)were excluded,leaving a total of 4246 participants for analysis.During a median follow-up of6.5 years,387 non-CV deaths,173 CV deaths,645 nonfatal major adverse CV events(MACEs)and 368 hospitalizations for congestive heart failure(CHF)were observed.OPG and FGF23 were associated with all outcomes,with the highest hazard ratios(HRs)for OPG.In the final Cox regression model,adjusted for CV risk factors,including kidney function and all other investigated biomarkers,each standard deviation increase in OPG was associated with non-CV death(HR 1.76,95%CI:1.35–2.30),CV death(HR 2.18,95%CI:1.50–3.16),MACE(HR 1.38,95%CI:1.12–1.71)and hospitalization for CHF(HR 2.05,95%CI:1.56–2.69).Out of the nine biomarkers examined,stratification based on serum OPG best identified the CKD patients who were at the highest risk for any adverse CV outcome and mortality.
基金
supported by grants from the Federal Ministry of Education and Research(Bundesministerium für Bildung und Forschung
BMBF
www.bmbf.de
FKZ 01ER 0804,01ER 0818,01ER 0819,01ER 0820,and 01ER 0821)
the Foundation for Preventive Medicine of the KfH(Kuratorium für Heimdialyze und Nierentransplantation e.V.-Stiftung Praventivmedizin),and corporate sponsors
further supported by the German Research Foundation(SFB/TRR219 project C1—Project-ID 322900939)
supported by the clinician scientist program of the German Society of Internal Medicine(DGIM)
the Else Kr?ner-FreseniusStiftung Excellence Fellowship(2022_EKES.03)
supported by a clinician scientist position funded by the German Research Council(DFG)within the clinical research unit 344(CRU344)
supported by BMBF within the framework of the e:Med research and funding concept(grant 01ZX1912B)。